reports
Soligenix, Inc. Impresses With Statistically Significant Topline Phase...
New York, New York--(Newsfile Corp. - March 20, 2020) - Soligenix, on Thursday, announced positive topline data for its lead CTCL drug candidate, SGX301. The published data demonstrated statistically significant efficacy results in treating this challenging and often debilitating chronic cancer. Additionally, this potentially transformative milestone for (NASDAQ: SNGX) positions the company to explore strategic partnership and commercialization opportunities to take advantage of what is an expected $250 million drug market opportunity. The positive preliminary topline results in the pivotal P...
Independent Case Study For Soligenix's CTCL Drug, SGX301, Drives Bulli...
Miami Beach, Florida--(Newsfile Corp. - February 20, 2020) - Soligenix may be nearing a transformative point in its history as data from its Phase 3 SGX301 (FLASH) trial to treat cutaneous T-cell lymphoma (CTCL) nears its release. The topline data from this late-stage study is expected in less than 40 days. And, if that release can validate data known from a recent case study performed by Dr. Brian Poligone, MD, Ph.D., then (NASDAQ: SNGX) may earn the first of several potential catalysts that can drive shareholder value higher. The Phase 3 clinical trial is targeting cutaneous T-cell lympho...
Soligenix Stock Jumps 95% YTD Ahead of Topline Data Release For SGX301...
Positive results, expected in Q1 2020, can position SGX301 as the first FDA-approved front-line therapy to treat Cutaneous T-cell Lymphoma (CTCL)Miami Beach, Florida--(Newsfile Corp. - January 30, 2020) - Soligenix (NASDAQ: SNGX) stock continued its price surge with gains exceeding 95% since the first of the year*. Investors are eyeing the near-term release of topline data for its late-stage drug candidate, SGX301, targeting the treatment of CTCL. If the results are consistent with the expectations from interim analysis guidance, the drug can become the first approved front-line therapy for t...
Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Relea...
Miami Beach, Florida--(Newsfile Corp. - October 22, 2019) - There are two things that developing biotechs need for success. First, they need a good drug. Second, they need cash to fund clinical trials. Soligenix has both (NASDAQ: SNGX). Combined, the two may offer investors a near-term opportunity to enjoy the rewards of both an FDA approval and the subsequent commercial launch of at least two promising drugs, SGX301 and SGX942, each targeting unmet medical needs. And, perhaps the best part of the consideration is that Soligenix is expected to deliver its first potentially transformative cat...
Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral...
Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ: SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head and neck cancer, an unmet medical need. And, as the release date approaches, investors may be looking for any clue they can get as to how the drug is performing. That clue, incidentally, may have been provided by the independent Data Monitoring Committee (DMC), who recently recommended that increase its patient enrollment by 70 patients to validate the trial's 90% statistical s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.